Skip to main contentSkip to navigationSkip to search
Curasight

Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik

May 21, 2021

Regulatory

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik.

The presentation will be webcasted live 10:55 (CET), Tuesday 25 May 2021.

For more information please click here

 

For more information regarding Curasight, please contact:
 

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.